SCHEMBL3452967

SCHEMBL3452967

CCOC(=O)c1ccc(Nc2nc3ccccc3c(=O)o2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.65
▸ KDM4E B2RXH2 5/20 0.65
▸ ALDH1A1 P00352 5/20 0.65
▸ MEN1 O00255 5/20 0.65
▸ KMT2A Q03164 5/20 0.65
▸ HPGD P15428 3/20 0.65
▸ GAA P10253 3/20 0.65
▸ NPSR1 Q6W5P4 3/20 0.65
▸ POLB P06746 2/20 0.65
▸ CYP1A2 P05177 2/20 0.65
▸ CYP3A4 P08684 2/20 0.65
▸ CYP2D6 P10635 2/20 0.65
▸ CYP2C9 P11712 2/20 0.65
▸ CYP2C19 P33261 2/20 0.65
▸ ELANE P08246 5/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ RAB9A P51151 3/20 0.59
▸ LMNA P02545 2/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ RXFP1 Q9HBX9 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2682409 0.85 RAB9A (0.61) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL3453070 0.83 ELANE (0.76) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL3452551 0.81 ELANE (0.68) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL20008615 0.81 MAPT (0.70) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL3452148 0.80 ELANE (0.80) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL3452604 0.78 ELANE (1.00) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL3452410 0.78 SLC2A1 (0.55) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL3453350 0.78 ELANE (0.80) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL3452939 0.77 ELANE (0.74) MAPTKDM4EALDH1A1KMT2AHPGD
SCHEMBL6999251 0.76 ELANE (0.60) MAPTALDH1A1MEN1KMT2AELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1144395-B1 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY ALIZYME THERAPEUTICS LTD (GB) 2005-04-20 — — EP claimed
US-6656934-B2 Enzyme inhibitor ALIZYME THERAPEUTICS LIMITED (GB) 2003-12-02 — — US claimed
US-20030191123-A1 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2003-10-09 — — US claimed
US-20030013707-A1 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2003-01-16 — — US claimed
US-7776853-B2 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2010-08-17 — — US disclosed
US-7776853-B2 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2010-08-17 — — US disclosed
US-7776853-B2 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2010-08-17 — — US disclosed
US-6656934-B2 Enzyme inhibitor ALIZYME THERAPEUTICS LIMITED (GB) 2003-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191123-A1 2-amino-benzoxazinone derivatives for the treatment of obesity CYP4X1, CYP2B6, BBOX1 MAPT 4577/4885KDM4E 556/4885ALDH1A1 159/4885
US-20030013707-A1 2-amino-benzoxazinone derivatives for the treatment of obesity CYP4X1, CYP2B6, BBOX1 MAPT 4577/4885KDM4E 556/4885ALDH1A1 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback